Predicting CSF α-Synuclein Seed Amplification Assay Status From Demographics and Clinical Data
The alpha-synuclein (α-syn) CSF seed amplification assay (CSF SAA) presents a promising diagnostic for Parkinson disease (PD) and other synucleinopathies. The objective of this study was to develop and externally validate models to predict probabilities of α-syn positive or negative status in vivo in a mixture of people with and without PD using easily accessible clinical predictors.
Authors
- Charles S. Venuto (ORCID: https://orcid.org/0000-0002-2394-9513)
- Lana M. Chahine (ORCID: https://orcid.org/0000-0003-2521-7196)
- Karl Kieburtz (ORCID: https://orcid.org/0000-0002-1645-6921)
- Konnor Herbst (ORCID: https://orcid.org/0000-0002-3629-9337)
Institutions
- University of Pittsburgh (US)
- University of Rochester (US)
Publication Details
- Journal
- Neurology Open Access
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1212/wn9.0000000000000008
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00